Caduceus USA Medical Pharmacy, LLC
Outcome
Caduceus USA Medical Pharmacy paid $250,000 and surrendered its DEA registration to resolve allegations of systemic controlled substance recordkeeping violations and unauthorized distribution.
Details
Caduceus USA Medical Pharmacy, LLC — CSA Recordkeeping Violations and DEA Registration Surrender (2020)
Outcome: Caduceus USA Medical Pharmacy paid $250,000 and surrendered its DEA registration to resolve allegations of systemic controlled substance recordkeeping violations and unauthorized distribution.
Caduceus USA Medical Pharmacy, LLC, a pharmacy located in Hapeville, Georgia, supplied controlled substances to a chain of occupational medicine clinics operated by an affiliated entity. The pharmacy came under DEA scrutiny for its handling of controlled substances purchased, maintained, and dispensed in connection with those clinic operations.
The government alleged multiple distinct violations of the Controlled Substances Act (CSA) and its implementing regulations. Specifically, Caduceus failed to keep accurate records of controlled substances it purchased and dispensed, failed to complete the federally required biennial inventory of all controlled substances on hand, failed to maintain records of controlled substances separately from its ordinary business records as required by 21 CFR Part 1304, and distributed a controlled substance in a manner not authorized by its DEA registration.
Caduceus acknowledged that it dispensed and distributed controlled substances in noncompliance with the CSA and its implementing regulations. As part of the settlement announced in November 2020 by the U.S. Attorney's Office for the Northern District of Georgia, the pharmacy agreed to pay $250,000 to the United States and to voluntarily surrender its DEA registration, permanently ending its ability to handle controlled substances.
The DEA emphasized that proper recordkeeping is essential to prevent the diversion of controlled substances into illicit channels. The surrender of registration marked a final closure of the pharmacy's controlled substance operations.
Primary Source: Pharmacy Pays $250,000 to Resolve Controlled Substances Act Violations — DOJ NDGA
How Crucible Prevents This
Crucible's audit-trail and recordkeeping enforcement controls would have flagged the absence of a biennial inventory, the failure to maintain controlled substance records separately from ordinary business records, and the distribution of a controlled substance not authorized by registration. Automated compliance checklists tied to DEA regulatory requirements (21 CFR Part 1304) would have surfaced these deficiencies before DEA investigation. Session-level documentation enforcement would have preserved the evidence chain needed for internal corrective action.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works